CYDY · Cytodyn Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - | $1.08M | $650.0K | $1.91M | $137.0K |
| SG&A | $1.65M | $1.80M | $1.71M | $2.29M | $1.51M | $1.60M | $2.31M | $2.76M | $2.69M | $5.04M |
| Total Operating Expenses | $6.30M | $21.69M | $4.95M | $3.71M | $4.00M | ($22.44M) | $3.40M | $3.41M | $4.61M | $23.16M |
| D&A | - | - | - | $8.0K | $7.0K | $5.0K | $8.0K | $7.0K | $10.0K | $54.0K |
| Operating Income | ($6.30M) | ($21.69M) | ($4.95M) | ($3.71M) | ($4.00M) | $22.44M | ($3.40M) | ($3.41M) | ($4.61M) | ($23.16M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | ($4.69M) | ($22.61M) | ($5.54M) | ($4.77M) | ($4.76M) | $19.23M | ($9.56M) | ($11.92M) | ($11.57M) | ($26.50M) |
| EPS - Basic | $0.00 | ($0.02) | $0.00 | $0.00 | $0.00 | $0.02 | ($0.01) | ($0.01) | ($0.01) | ($0.03) |
| EPS - Diluted | $0.00 | ($0.02) | $0.00 | $0.00 | $0.00 | $0.02 | ($0.01) | ($0.01) | ($0.01) | ($0.03) |
Balance Sheet
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $15.65M | $4.98M | $9.33M | $11.90M | $16.40M | $24.92M | $3.11M | $1.40M | $2.03M | $2.54M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | $0 | - | - | $0 |
| Accounts Payable | $13.48M | $14.24M | $14.18M | $14.69M | $15.13M | $14.16M | $29.56M | $62.08M | $62.77M | $62.73M |
| Current Assets | $18.44M | $8.84M | $13.35M | $17.88M | $20.98M | $27.74M | $10.81M | $9.91M | $11.97M | $10.80M |
| Total Assets | $18.50M | $8.94M | $13.48M | $18.05M | $21.19M | $28.02M | $11.14M | $10.27M | $12.41M | $11.29M |
| Current Liabilities | $50.43M | $85.11M | $69.42M | $70.52M | $70.56M | $69.56M | $84.18M | $129.48M | $129.05M | $119.80M |
| Long-term Debt | $40.53M | $42.17M | $43.78M | $45.35M | $45.84M | $45.31M | $45.02M | $44.25M | $44.87M | $45.73M |
| Total Liabilities | $122.78M | $128.68M | $112.99M | $114.09M | $114.17M | $113.23M | $127.89M | $129.65M | $129.30M | $120.79M |
| Stockholders' Equity | ($104.29M) | ($119.75M) | ($99.50M) | ($96.04M) | ($92.98M) | ($85.21M) | ($116.76M) | ($119.38M) | ($116.89M) | ($109.50M) |
| Retained Earnings | ($920.62M) | ($915.93M) | ($893.33M) | ($887.79M) | ($881.83M) | ($872.30M) | ($891.53M) | ($874.74M) | ($853.26M) | ($841.69M) |
Cash Flow
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($2.45M) | - | - | $5.44M | - | - | ($4.50M) | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | - | - | ($121.0K) | - | - | $9.67M | - | - | $4.02M | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | 0.0% | - | - | - | - |
| Return on assets | -25.4% | -253.0% | -41.1% | -26.4% | -22.5% | 68.6% | -85.9% | -116.1% | -93.2% | -234.6% |
| Return on equity | 4.5% | 18.9% | 5.6% | 5.0% | 5.1% | -22.6% | 8.2% | 10.0% | 9.9% | 24.2% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.37 | 0.10 | 0.19 | 0.25 | 0.30 | 0.40 | 0.13 | 0.08 | 0.09 | 0.09 |
| Quick ratio | 0.37 | 0.10 | 0.19 | 0.25 | 0.30 | 0.40 | 0.13 | 0.08 | 0.09 | 0.09 |
| Cash ratio | 0.31 | 0.06 | 0.13 | 0.17 | 0.23 | 0.36 | 0.04 | 0.01 | 0.02 | 0.02 |
| Leverage | ||||||||||
| Debt / Equity | -0.39 | -0.35 | -0.44 | -0.47 | -0.49 | -0.53 | -0.39 | -0.37 | -0.38 | -0.42 |
| Debt / Assets | 2.19 | 4.72 | 3.25 | 2.51 | 2.16 | 1.62 | 4.04 | 4.31 | 3.62 | 4.05 |
| Debt / EBITDA | - | - | - | - | - | 2.02 | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | -0.18 | -0.07 | -0.14 | -0.19 | -0.23 | -0.33 | -0.10 | -0.09 | -0.11 | -0.10 |
| Liabilities / Assets | 6.64 | 14.40 | 8.38 | 6.32 | 5.39 | 4.04 | 11.48 | 12.62 | 10.42 | 10.70 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -57.5% | -485.1% | - | -9.1% | -17.3% | - | 85.3% | 12.9% | 52.5% | - |
| Net income growth (YoY) | 1.4% | -374.1% | - | 50.1% | 60.1% | - | 63.9% | 13.0% | 44.9% | - |
| EPS growth (YoY) | - | - | - | - | - | - | 66.7% | 50.0% | 66.7% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -12.2% | -24.7% | -16.8% | 17.7% | 22.1% | 27.1% | -6.6% | -11.6% | -23.9% | -16.0% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing CytoDyn Inc. against the 5 most active filers in the same SIC group.